Tirzepatide (Mounjaro, Zepbound) targets two pathways and tends to produce greater weight loss in head-to-head studiesroughly 20% body weight loss on tirzepatide vs 15% on semaglutide
With MDWatch, Tirzepatide is $140 for a 4-week supply and Semaglutide is $90
study likely suffered from detection bias and confounding by obesity, as patients taking GLP-1s tend to see their doctors more frequently, leading to higher detection rates of slow-growing thyroid nodules
Over the last few years, the interest in GLP-1 drugs for weight loss has skyrocketed
More recently, the FDA has approved several GLP-1 agonists for weight loss in people with obesity who do not have diabetes
All adults had a recorded diagnosis of obesity defined as BMI of 30 kg/m 2 or higher or BMI of 27 kg/m 2 to 29.9 kg/m 2 with at least one weight-related comorbidity